Upgrade to SI Premium - Free Trial

Esperion Therapeutics (ESPR) PT Raised to $5 at Citizens After Q4 Results

March 13, 2026 5:40 AM
Citizens analyst Jason N. Butler raised the price target on Esperion Therapeutics (NASDAQ: ESPR) to $5.00 (from $4.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change